Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Verve Therapeutics Inc.

    NASDAQ: VERV · Real-Time Price · USD
    11.13
    0.03 (0.27%)
    At close: Jul 24, 2025, 3:59 PM
    0.27%
    Bid 11.2
    Market Cap 994.04M
    Revenue (ttm) 59.61M
    Net Income (ttm) -181.01M
    EPS (ttm) -2.11
    PE Ratio (ttm) -5.274881516587678
    Forward PE -3.58
    Analyst Hold
    Ask 11.22
    Volume 10,306,656
    Avg. Volume (20D) 5,716,259
    Open 11.13
    Previous Close 11.10
    Day's Range 11.13 - 11.13
    52-Week Range 2.87 - 11.40
    Beta 2.24

    About VERV

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VERV
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VERV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Verve Therapeutics Inc. is scheduled to release its earnings on Aug 26, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +81.5%
    Verve Therapeutics shares are trading higher after... Unlock content with Pro Subscription
    3 months ago
    +3.61%
    Verve Therapeutics shares are trading higher after the company reported a year-over-year increase for Q1 EPS results.
    news image

    3 weeks ago · marketbeat.com

    3 Bullish Biotech Stocks With Explosive Growth Trends

    Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo...

    news image

    1 month ago · fool.com

    Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

    Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicin...

    news image

    1 month ago · businesswire.com

    VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

    NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve...

    news image

    1 month ago · zacks.com

    Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

    LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

    news image

    1 month ago · zacks.com

    Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

    VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

    news image

    1 month ago · businesswire.com

    VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

    NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareho...

    news image

    1 month ago · fool.com

    Why Verve Therapeutics Stock Is Skyrocketing Today

    Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.

    news image

    1 month ago · schaeffersresearch.com

    Biotech Stock Surging on Billion-Dollar Buyout

    Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly (LLY) will buy the company for $10.50 per share, or roughly $1.3 billion.

    news image

    1 month ago · investors.com

    Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

    Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.

    news image

    1 month ago · businesswire.com

    Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

    MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to le...

    Add to Watchlist